Characteristics of patients with CSF+ vs CSF− involvement of BPDCN
| Patient variable . | CSF+ (n = 23) . | CSF− (n = 80) . | P . |
|---|---|---|---|
| Sex | |||
| Male | 17 (74) | 66 (83) | .36 |
| Female | 6 (26) | 14 (18) | |
| Median age at diagnosis, y (range) | 63 (2-82) | 66.5 (20-86) | .23 |
| Median WBCs at dx, ×109/L (range) | 6 (1.7-54.3) | 5.8 (1.5-179) | .92 |
| Median Hgb at dx, g/dL (range) | 11.2 (6.8-15.9) | 13.2 (8-17.1) | .02 |
| Median platelets at dx, ×109/L (range) | 102 (11-365) | 152 (18-407) | .08 |
| Median LDH at dx, U/L (range) | 529 (191-1170) (n = 6) | 511 (121-4108) (n = 24) | .53 |
| Median BM-Bl at dx, percentage (range) | 46 (0-95) | 3.5 (0-94) | .01 |
| Median PB-Bl at dx, percentage (range) | 4 (0-67) (n = 8) | 0 (0-61) (n = 28) | .05 |
| Involvement of BPDCN disease | |||
| Skin | 16 (70) | 65 (81) | .40 |
| Lymph node | 7 (30) | 17 (21) | .51 |
| Bone marrow | 22 (96) | 51 (64) | .02 |
| Cytogenetics | |||
| Complex cytogenetics | 8 (35) | 13 (16) | .05 |
| Diploid cytogenetics | 12 (52) | 51 (64) | .32 |
| Mutations | |||
| TET2 | 11/11 (100) | 36/50 (72) | .05 |
| ASXL1 | 3/11 (27) | 19/50 (38) | .50 |
| RAS | 3/12 (25) | 8/52 (15) | .43 |
| Frontline therapy | |||
| AML-based | 3 (13) | 3 (4) | — |
| Bortezomib-based | 1 (4) | 1 (1) | — |
| CHOP | 2 (9) | 6 (8) | — |
| HCVAD | 8 (35) | 24 (30) | — |
| Hypomethylator-based | 1 (4) | 3 (4) | — |
| Other | 2 (9) | 7 (9) | — |
| SL-401 (tagraxofusp) | 5 (22) | 32 (40) | — |
| SL-401+HCVAD, with or without venetoclax | 1 (4) | 2 (3) | — |
| Unknown | 0 (0) | 2 (3) | — |
| Hematopoietic stem cell transplant | 11 (48) | 34 (43) | .70 |
| Allogeneic | 10 (91) | 24 (71) | — |
| Autologous | 1 (9) | 10 (29) | — |
| BPDCN status at time of CNS* | |||
| Frontline presentation | 13 (57) | — | — |
| Relapsed/refractory disease | 10 (43) | — | — |
| Symptomatic at the time of CNS+ | 10 (43) | — | — |
| Asymptomatic at the time of CNS+ | 13 (57) | — | — |
| Median months from BPDCN diagnosis to CNS+ (range) | 3.6 (0-36) | — | — |
| Median months to CNS+ (not including those found at the time of BPDCN diagnosis; n = 18 (range) | 5.8 (1.4-35.9) | — | — |
| Median OS, mo | |||
| CSF+ (n = 23) vs CSF− (n = 80) | 22.9 | 17.8 | .22 |
| Early CSF+ (n = 13) vs early CSF− (n = 90) | 35.1 | 20.2 | .19 |
| Median CR1 duration, mo | 20.6 | 38.6 | .21 |
| Patient variable . | CSF+ (n = 23) . | CSF− (n = 80) . | P . |
|---|---|---|---|
| Sex | |||
| Male | 17 (74) | 66 (83) | .36 |
| Female | 6 (26) | 14 (18) | |
| Median age at diagnosis, y (range) | 63 (2-82) | 66.5 (20-86) | .23 |
| Median WBCs at dx, ×109/L (range) | 6 (1.7-54.3) | 5.8 (1.5-179) | .92 |
| Median Hgb at dx, g/dL (range) | 11.2 (6.8-15.9) | 13.2 (8-17.1) | .02 |
| Median platelets at dx, ×109/L (range) | 102 (11-365) | 152 (18-407) | .08 |
| Median LDH at dx, U/L (range) | 529 (191-1170) (n = 6) | 511 (121-4108) (n = 24) | .53 |
| Median BM-Bl at dx, percentage (range) | 46 (0-95) | 3.5 (0-94) | .01 |
| Median PB-Bl at dx, percentage (range) | 4 (0-67) (n = 8) | 0 (0-61) (n = 28) | .05 |
| Involvement of BPDCN disease | |||
| Skin | 16 (70) | 65 (81) | .40 |
| Lymph node | 7 (30) | 17 (21) | .51 |
| Bone marrow | 22 (96) | 51 (64) | .02 |
| Cytogenetics | |||
| Complex cytogenetics | 8 (35) | 13 (16) | .05 |
| Diploid cytogenetics | 12 (52) | 51 (64) | .32 |
| Mutations | |||
| TET2 | 11/11 (100) | 36/50 (72) | .05 |
| ASXL1 | 3/11 (27) | 19/50 (38) | .50 |
| RAS | 3/12 (25) | 8/52 (15) | .43 |
| Frontline therapy | |||
| AML-based | 3 (13) | 3 (4) | — |
| Bortezomib-based | 1 (4) | 1 (1) | — |
| CHOP | 2 (9) | 6 (8) | — |
| HCVAD | 8 (35) | 24 (30) | — |
| Hypomethylator-based | 1 (4) | 3 (4) | — |
| Other | 2 (9) | 7 (9) | — |
| SL-401 (tagraxofusp) | 5 (22) | 32 (40) | — |
| SL-401+HCVAD, with or without venetoclax | 1 (4) | 2 (3) | — |
| Unknown | 0 (0) | 2 (3) | — |
| Hematopoietic stem cell transplant | 11 (48) | 34 (43) | .70 |
| Allogeneic | 10 (91) | 24 (71) | — |
| Autologous | 1 (9) | 10 (29) | — |
| BPDCN status at time of CNS* | |||
| Frontline presentation | 13 (57) | — | — |
| Relapsed/refractory disease | 10 (43) | — | — |
| Symptomatic at the time of CNS+ | 10 (43) | — | — |
| Asymptomatic at the time of CNS+ | 13 (57) | — | — |
| Median months from BPDCN diagnosis to CNS+ (range) | 3.6 (0-36) | — | — |
| Median months to CNS+ (not including those found at the time of BPDCN diagnosis; n = 18 (range) | 5.8 (1.4-35.9) | — | — |
| Median OS, mo | |||
| CSF+ (n = 23) vs CSF− (n = 80) | 22.9 | 17.8 | .22 |
| Early CSF+ (n = 13) vs early CSF− (n = 90) | 35.1 | 20.2 | .19 |
| Median CR1 duration, mo | 20.6 | 38.6 | .21 |
Data are number of patients (percentage of study group), unless otherwise stated. Bold P-values indicate statistically significant differences between study groups.
BM-Bl, bone marrow blast percentage; dx, diagnosis; Hgb, hemoglobin concentration; LDH, lactate dehydrogenase; PB-Bl, peripheral blood blast percentage; SL-401, tagraxofusp-erzs; WBC, white blood cell count.
CNS includes patients who never underwent lumbar puncture analysis (n = 74).